Aimmune Therapeutics, Inc. (AIMT): Price and Financial Metrics
GET POWR RATINGS... FREE!
AIMT Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for AIMT is 0 -- better than only 9% of US stocks.
- AIMT's price/sales ratio is 3,925.87; that's higher than the P/S ratio of 99.73% of US stocks.
- With a year-over-year growth in debt of 177.57%, Aimmune Therapeutics Inc's debt growth rate surpasses 91.61% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Aimmune Therapeutics Inc, a group of peers worth examining would be RVNC, ADVM, MRTX, AUPH, and VTVT.
- Visit AIMT's SEC page to see the company's official filings. To visit the company's web site, go to www.aimmune.com.
AIMT Stock Price Chart Interactive Chart >
AIMT Price/Volume Stats
|Current price||$34.49||52-week high||$37.00|
|Prev. close||$34.59||52-week low||$10.09|
|Day high||$34.56||Avg. volume||1,714,599|
|50-day MA||$25.92||Dividend yield||N/A|
|200-day MA||$21.96||Market Cap||2.26B|
Aimmune Therapeutics, Inc. (AIMT) Company Bio
Aimmune Therapeutics is a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. The company was founded in 2011 and is based in Brisbane, California.
AIMT Latest News Stream
|Loading, please wait...|
AIMT Latest Social Stream
View Full AIMT Social Stream
Latest AIMT News From Around the Web
Below are the latest news stories about Aimmune Therapeutics Inc that investors may wish to consider to help them evaluate AIMT as an investment opportunity.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT
NEW YORK , Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City , is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") ( AIMT ) relating to the sale of the Company to Sociétés des Produits Nestlé, S.A. Under the terms of the agreement, Aimmune shareholders are anticipated to receive $34.50 per share for each share of Aimmune they own. … Full story available on Benzinga.com
This weekly column explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position or action we have...
Development of Needle Free Alternatives for Treatment of Anaphylaxis Underway as Aquestive Therapeutics Launches Phase 1 Clinical Trial - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--ResearchAndMarkets.com published a new article on the allergy drugs industry "Allergy Drugs" Nestle has agreed to buy Aimmune Therapeutics Inc in a $2.6 billion deal. Nestle has built a large health science business focused on dietary management and the deal will add Aimmunes's Palforzia to its portfolio. Palforzia is the first FDA approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children and teenagers. The drug is derived from
Investment Thesis Earlier this year, Aimmune Therapeutics, Inc. (AIMT) unveiled Palforzia, the first and only FDA approved therapy to suppress the effects of peanut allergy. The lockdown measures hindered its market launch, and the company failed to realize sales to arrest the stock’s decline. Despite a rich portfolio of drugs...
AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aimmune Therapeutics Inc. - AIMT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Aimmune Therapeutics Inc. (NasdaqGS: AIMT) to Sociétés des Produits Nestlé, S.A. Under the terms of the proposed transaction, shareholders of Aimmune will receive only $34.50 in cash for each share of Aimmune that they own. KSF is seeking to determine whether this consideration and the process that led to i
AIMT Price Returns